印度尼西亚乙型肝炎核心抗原(HBcAg)在乳酸乳球菌中作为潜在治疗性疫苗的构建和表达

Q3 Agricultural and Biological Sciences

BioTechnologia Pub Date : 2019-01-01 DOI:10.5114/BTA.2019.83210

R. Anwar, A. Z. Mustopa, R. A. Ningrum, S. Suharsono

{"title":"印度尼西亚乙型肝炎核心抗原(HBcAg)在乳酸乳球菌中作为潜在治疗性疫苗的构建和表达","authors":"R. Anwar, A. Z. Mustopa, R. A. Ningrum, S. Suharsono","doi":"10.5114/BTA.2019.83210","DOIUrl":null,"url":null,"abstract":"The hepatitis B core antigen protein (HBcAg) may induce proliferation of B, T, and cytotoxic T cells; induce immune responses; and provide T-cell resources for antibody responses after vaccination (Freivalds et al., 2011). Thus, HBcAg may be used as a therapeutic vaccine in patients with chronic hepatitis B virus (HBV) infection. This article describes a study on the construction and expression of HBcAg in Lactococcus lactis by the nisin-controlled expression (NICE) system. An HBcAg gene, the HBV subgenotype B3 that is dominant in Indonesia, was successfully cloned into a pNZ8148 vector and resulted in the formation of the transformant L. lactis NZ3900 pNZ818-HBcAg. The HBcAg protein measured 21 kDa. Induction with 10 ng/ml nisin significantly increased the concentration of the expressed protein. Western blotting and dot blot hybridization analysis indicated that the HBcAg proteins confirmed the expression of an antibody, with potential to become an HBV therapeutic vaccine.","PeriodicalId":8999,"journal":{"name":"BioTechnologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Construction and expression of indonesian hepatitis B core antigen (HBcAg) in Lactococcus lactis as potential therapeutic vaccine\",\"authors\":\"R. Anwar, A. Z. Mustopa, R. A. Ningrum, S. Suharsono\",\"doi\":\"10.5114/BTA.2019.83210\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The hepatitis B core antigen protein (HBcAg) may induce proliferation of B, T, and cytotoxic T cells; induce immune responses; and provide T-cell resources for antibody responses after vaccination (Freivalds et al., 2011). Thus, HBcAg may be used as a therapeutic vaccine in patients with chronic hepatitis B virus (HBV) infection. This article describes a study on the construction and expression of HBcAg in Lactococcus lactis by the nisin-controlled expression (NICE) system. An HBcAg gene, the HBV subgenotype B3 that is dominant in Indonesia, was successfully cloned into a pNZ8148 vector and resulted in the formation of the transformant L. lactis NZ3900 pNZ818-HBcAg. The HBcAg protein measured 21 kDa. Induction with 10 ng/ml nisin significantly increased the concentration of the expressed protein. Western blotting and dot blot hybridization analysis indicated that the HBcAg proteins confirmed the expression of an antibody, with potential to become an HBV therapeutic vaccine.\",\"PeriodicalId\":8999,\"journal\":{\"name\":\"BioTechnologia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BioTechnologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/BTA.2019.83210\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Agricultural and Biological Sciences\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BioTechnologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/BTA.2019.83210","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Agricultural and Biological Sciences","Score":null,"Total":0}

引用次数: 2

摘要

乙型肝炎核心抗原蛋白(HBcAg)可诱导B、T和细胞毒性T细胞的增殖;诱导免疫反应;并为疫苗接种后的抗体反应提供t细胞资源(Freivalds et al.， 2011)。因此，HBcAg可作为慢性乙型肝炎病毒(HBV)感染患者的治疗性疫苗。本文利用nisin-controlled expression (NICE)系统研究了HBcAg在乳酸乳球菌中的构建和表达。在印度尼西亚占主导地位的HBV亚基因型B3 HBcAg基因成功地克隆到pNZ8148载体中，并形成了转化L. lactis NZ3900 pNZ818-HBcAg。HBcAg蛋白测定值为21 kDa。10 ng/ml的nisin诱导显著提高了表达蛋白的浓度。Western blotting和dot blot杂交分析表明，HBcAg蛋白证实了一种抗体的表达，具有成为HBV治疗性疫苗的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Construction and expression of indonesian hepatitis B core antigen (HBcAg) in Lactococcus lactis as potential therapeutic vaccine

The hepatitis B core antigen protein (HBcAg) may induce proliferation of B, T, and cytotoxic T cells; induce immune responses; and provide T-cell resources for antibody responses after vaccination (Freivalds et al., 2011). Thus, HBcAg may be used as a therapeutic vaccine in patients with chronic hepatitis B virus (HBV) infection. This article describes a study on the construction and expression of HBcAg in Lactococcus lactis by the nisin-controlled expression (NICE) system. An HBcAg gene, the HBV subgenotype B3 that is dominant in Indonesia, was successfully cloned into a pNZ8148 vector and resulted in the formation of the transformant L. lactis NZ3900 pNZ818-HBcAg. The HBcAg protein measured 21 kDa. Induction with 10 ng/ml nisin significantly increased the concentration of the expressed protein. Western blotting and dot blot hybridization analysis indicated that the HBcAg proteins confirmed the expression of an antibody, with potential to become an HBV therapeutic vaccine.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

BioTechnologia Agricultural and Biological Sciences-Plant Science

CiteScore

1.60

自引率

0.00%

发文量

审稿时长

8 weeks

期刊介绍： BIOTECHNOLOGIA – a high standard, peer-reviewed, quarterly magazine, providing a medium for the rapid publication of research reports and review articles on novel and innovative aspects of biotechnology, computational biology and bionanotechnology.